PBE vs. IDNA
Compare and contrast key facts about Invesco Dynamic Biotechnology & Genome ETF (PBE) and iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA).
PBE and IDNA are both exchange-traded funds (ETFs), meaning they are traded on stock exchanges and can be bought and sold throughout the day. PBE is a passively managed fund by Invesco that tracks the performance of the Dynamic Biotech & Genome Intellidex Index (AMEX). It was launched on Jun 23, 2005. IDNA is a passively managed fund by iShares that tracks the performance of the NYSE FactSet Global Genomics and Immuno Biopharma Index. It was launched on Jun 11, 2019. Both PBE and IDNA are passive ETFs, meaning that they are not actively managed but aim to replicate the performance of the underlying index as closely as possible.
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: PBE or IDNA.
Key characteristics
| PBE | IDNA | |
|---|---|---|
| YTD Return | 5.55% | 7.10% |
| 1Y Return | 29.67% | 37.02% |
| 3Y Return (Ann) | -2.54% | -20.34% |
| 5Y Return (Ann) | 5.94% | -0.78% |
| Sharpe Ratio | 1.62 | 1.73 |
| Sortino Ratio | 2.37 | 2.47 |
| Omega Ratio | 1.28 | 1.29 |
| Calmar Ratio | 0.87 | 0.60 |
| Martin Ratio | 7.72 | 7.80 |
| Ulcer Index | 4.05% | 5.13% |
| Daily Std Dev | 19.28% | 23.17% |
| Max Drawdown | -45.69% | -68.26% |
| Current Drawdown | -17.06% | -54.64% |
Correlation
The correlation between PBE and IDNA is 0.86, which is considered to be high. That indicates a strong positive relationship between their price movements. Having highly-correlated positions in a portfolio may signal a lack of diversification, potentially leading to increased risk during market downturns.
Performance
PBE vs. IDNA - Performance Comparison
In the year-to-date period, PBE achieves a 5.55% return, which is significantly lower than IDNA's 7.10% return. The chart below displays the growth of a $10,000 investment in both assets, with all prices adjusted for splits and dividends.
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
PBE vs. IDNA - Expense Ratio Comparison
PBE has a 0.59% expense ratio, which is higher than IDNA's 0.47% expense ratio.
Risk-Adjusted Performance
PBE vs. IDNA - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Invesco Dynamic Biotechnology & Genome ETF (PBE) and iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
PBE vs. IDNA - Dividend Comparison
PBE's dividend yield for the trailing twelve months is around 0.05%, less than IDNA's 1.14% yield.
| TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
PBE Invesco Dynamic Biotechnology & Genome ETF | 0.05% | 0.02% | 0.00% | 0.00% | 0.04% | 0.00% | 0.00% | 0.57% | 0.38% | 1.12% | 0.55% |
IDNA iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund | 1.14% | 1.04% | 0.54% | 0.70% | 0.26% | 0.80% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Drawdowns
PBE vs. IDNA - Drawdown Comparison
The maximum PBE drawdown since its inception was -45.69%, smaller than the maximum IDNA drawdown of -68.26%. Use the drawdown chart below to compare losses from any high point for PBE and IDNA. For additional features, visit the drawdowns tool.
Volatility
PBE vs. IDNA - Volatility Comparison
Invesco Dynamic Biotechnology & Genome ETF (PBE) has a higher volatility of 4.66% compared to iShares Genomics Immunology and Healthcare ETF Genomics Immunology and Healthcare Fund (IDNA) at 4.23%. This indicates that PBE's price experiences larger fluctuations and is considered to be riskier than IDNA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.